Trial Profile
Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel) in Subjects 11 to 55 Years of Age in South Korea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2017
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Diphtheria; Meningococcal infections; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 18 Jul 2013 Planned End Date changed from 1 Nov 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.